Program
benzgalantamine gluconate
Its studies are mostly in Alzheimer Disease, led by Alpha Cognition.
Furthest: phase 4, since May 19, 20261 company-led study, 1 open or runningNext primary completion: Apr 2027 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alpha Cognition | 11 open or running | phase 4since May 19, 2026 | May 19, 2026 | Apr 2027phase 4 · NCT07633470 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 19, 2026First study: phase 4 study in Alzheimer DiseaseFirst studyNCT07633470 · 150 planned · United States
Ahead
- Apr 2027Primary completion: phase 4 study in Alzheimer DiseaseNCT07633470
TargetBeta
ACHE →read by rule
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule
Other programs on ACHE
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Donepezilrule | Eisai | phase 4 | 83 |
| huperzine Arule | wanbangde-pharmaceutical-group-co-ltd | phase 4 | 7 |
| Z 338rule | Zeria Pharmaceutical | phase 3 | 12 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07633470Alzheimer Disease · United States | 4 | Recruiting | Apr 2027 | 150 |
How it is read
Names in the registry
- “Zunveyl®”, 1 entry
Conditions, from the studies’ own filings
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.